Earnings ·
Revvity reports Q3 revenue of $729M, raises full-year adjusted EPS guidance to $5.40-$5.45
RVTYRevvity, Inc.
Revvity reported third-quarter revenue of $729 million and GAAP earnings per share from continuing operations of $0.56, compared to $0.41 in the prior year period. Adjusted EPS reached $1.38, up from $1.18 a year ago. The company raised its full-year 2026 pro forma adjusted EPS guidance to $5.40-$5.45 and forecast total revenue of approximately $2.86 billion. Revvity also provided pro forma financials reflecting the probable sale of its China Immunodiagnostics business for up to $200 million, expected to close by the end of 2027. The company operates in the health science industry, providing technologies and services for discovery, development, diagnosis, and cure.